Sagimet Biosciences Inc.
HealthcareNASDAQ:SGMT · NASDAQ Global Market
+$0.05 today
Vol 0.46M · Avg 1.48M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.8%
avg -7.7%
ROIC
-51.0%
avg -63.4%
ROA
-43.8%
avg -54.2%
Analysis
ROA is currently the strongest return metric at -43.8% versus its period average of -54.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David A. Happel | Chief Executive Officer, President & Director | $943,883.00 | — | 64 | $300,000.00 | 0.92% |
Elizabeth Rozek | Chief Legal & Administrative Officer | $669,897.00 | — | 54 | $100,000.00 | 0.31% |
Andreas Grauer | Chief Medical Officer | $669,064.00 | — | 65 | $35,000.00 | 0.11% |
Eduardo Bruno Martins DPhil | Chief Medical Officer | $669,064.00 | — | 63 | $147,296.00 | 0.45% |
Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | $598,045.00 | — | 50 | $50,000.00 | 0.15% |
Marie O'Farrell | Chief Scientific Officer | — | — | — | — | — |
Robert D'Urso | Senior Vice President of New Products | — | — | — | — | — |
Lucas Pelkmans | Co-Founder | — | — | — | — | — |
Urs Greber | Co-Founder | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$1.17M
Net Sentiment
$1.17M
Net selling
Most Active
Happel David
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $1.17M over the last 12 months. That adds up to net selling of $1.17M. Happel David was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +99.6% (7yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Forward estimates point to Revenue at +99.6% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Assembly Biosciences, Inc.
NASDAQ:ASMB
$364.90M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Who manages SGMT?
Sagimet Biosciences Inc. (SGMT) lists 9 active executives. The top listed executive is Marie O'Farrell, Chief Scientific Officer.
Are SGMT insiders buying or selling?
Recent insider activity shows net buying of $16.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.